{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:04:08Z","timestamp":1787799848359,"version":"build-2784847793"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This meta-analysis aims to evaluate the efficacy of omalizumab (as monotherapy or combined with OIT) in achieving target maintenance dose (TMD), and its safety profile in terms of treatment-emergent adverse events (TEAEs) and epinephrine use, in children and young adults with IgE-mediated food allergy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, and Web of Science databases to identify relevant randomized controlled trials (RCTs) and controlled clinical trials (CCTs). Eligible studies compared omalizumab-based interventions (monotherapy or OIT combination) with control strategies (placebo, placebo plus OIT, or strict allergen avoidance) in children and adolescents with IgE-mediated food allergy. The primary efficacy endpoint was the achievement of a target maintenance dose (TMD), defined as the maximum allergen dose tolerated without dose-limiting symptoms. Safety outcomes included the incidence of treatment-emergent adverse events (TEAEs) and the requirement for epinephrine administration. Data synthesis employed random-effects models to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight studies (n = 734 participants) met the inclusion criteria, comprising 7 RCTs and 1 CCT. Pooled analysis demonstrated that omalizumab-based therapy significantly increased the likelihood of achieving a clinically meaningful TMD compared to control interventions (RR = 3.07, 95% CI: 1.42\u20136.62; p &amp;lt; 0.001), with consistent efficacy observed across subgroups of multiple food allergies, peanut allergy. With respect to safety, no statistically significant difference was noted in the overall incidence of TEAEs between the omalizumab and control groups (RR = 1.02, 95% CI: 0.74\u20131.41; p = 0.889). Similarly, the rate of epinephrine use during oral food challenges or treatment did not differ significantly between groups (RR = 0.59, 95% CI: 0.07\u20134.78; p = 0.099), though the wide confidence intervals indicate substantial uncertainty due to limited data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis provides robust evidence that omalizumab, either as monotherapy or in combination with OIT, significantly enhances allergen tolerance in children and young adults with IgE-mediated food allergy. Importantly, this therapeutic benefit is not accompanied by a significant increase in the overall burden of adverse events or epinephrine use relative to control strategies. Omalizumab thus represents a valuable therapeutic option for improving desensitization outcomes in this vulnerable population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>\n                      , identifier CRD420251087191.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1690650","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:13:09Z","timestamp":1761192789000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Systematic review and meta-analysis of omalizumab for IgE-mediated food allergy in children and young adults"],"prefix":"10.3389","volume":"16","author":[{"given":"Ya","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/105984050001600202","article-title":"The challenge of making the school environment safe for children with food allergies","volume":"16","author":"Gaudreau","year":"2001","journal-title":"J Sch Nurs"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e12064","DOI":"10.1002\/clt2.12064","article-title":"Incidence of anaphylaxis and accidental peanut exposure: A systematic review","volume":"11","author":"Muraro","year":"2021","journal-title":"Clin Transl Allergy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.9b08245","article-title":"Effect of ultrasound treatment on allergenicity reduction of milk casein via colloid formation","volume":"68","author":"Wang","year":"2020","journal-title":"J Agric Food Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.05.010","article-title":"Seasonal-specific variations of the upper airway microbiome and childhood asthma: Friend or foe","volume":"150","author":"Bellanti","year":"2022","journal-title":"J Allergy Clin Immumol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/nu14194016","article-title":"The role of infant formulas in the primary prevention of allergies in non-breastfed infants at risk of developing allergies-recommendations from a multidisciplinary group of experts","volume":"14","author":"Dias","year":"2022","journal-title":"Nutrients"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2021.01.006","article-title":"Psychosocial aspects of food allergy: resiliency, challenges and opportunities","volume":"41","author":"Rubeiz","year":"2021","journal-title":"Immunol Allergy Clin North Am"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-024-01134-0","article-title":"Food insecurity and health inequities in food allergy","volume":"24","author":"Jefferson","year":"2024","journal-title":"Curr Allergy Asthma Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0000000000000269","article-title":"Doctor, my child is bullied: food allergy management in schools","volume":"16","author":"Egan","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.12.021","article-title":"Quality of life in food allergic children: Results from 174 quality-of-life patient questionnaires","volume":"124","author":"Miller","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11882-020-0898-7","article-title":"Epidemiology and burden of food allergy","volume":"20","author":"Warren","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0000000000001058","article-title":"New approaches in childhood IgE-mediated food allergy treatment","volume":"25","author":"Gurel","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e328337bd3a","article-title":"Should avoidance of foods be strict in prevention and treatment of food allergy","volume":"10","author":"Kim","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2012.04028.x","article-title":"Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children","volume":"42","author":"Thyagarajan","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2011.03722.x","article-title":"Oral rush desensitization to egg: efficacy and safety","volume":"41","author":"Garc\u00eda Rodr\u00edguez","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2007.00556.x","article-title":"Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children","volume":"18","author":"Iba\u00f1ez","year":"2007","journal-title":"Pediatr Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jaci.2016.07.030","article-title":"Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy","volume":"139","author":"Virkud","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041563","article-title":"The etiology of igE-mediated food allergy: potential therapeutics and challenges","volume":"26","author":"Carnazza","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.iac.2019.09.005","article-title":"Peanut oral immunotherapy: state of the art","volume":"40","author":"Tang","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2021.01.009","article-title":"Dietary management of food allergy","volume":"41","author":"Durban","year":"2021","journal-title":"Immunol Allergy Clin North Am"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.2001.01181.x","article-title":"Human mast cell progenitors in peripheral blood from atopic subjects with high IgE levels","volume":"31","author":"Nomura","year":"2001","journal-title":"Clin Exp Allergy"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Jessica","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312382","article-title":". Omalizumab for the treatment of multiple food allergies.","volume":"390","author":"Robert","year":"2024","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13469","article-title":"Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents","volume":"49","author":"Brandstr\u00f6m","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e70002","DOI":"10.1002\/clt2.70002","article-title":"GA(2)LEN ANACARE consensus statement: Potential of omalizumab in food allergy management","volume":"14","author":"Zuberbier","year":"2024","journal-title":"Clin Transl Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0000000000000900","article-title":"Biologicals in IgE-mediated food allergy","volume":"23","author":"Mutarelli","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2500\/aap.2010.31.3304","article-title":"Effects of omalizumab in patients with food allergy","volume":"31","author":"Rafi","year":"2010","journal-title":"Allergy Asthma Proc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"B30","doi-asserted-by":"publisher","first-page":"14898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/s2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eclinm.2018.12.006","article-title":"A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals","volume":"7","author":"Andorf","year":"2019","journal-title":"E Clin Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/all.16046","article-title":"A randomized, double-blind placebo-controlled study on the efficacy of Omalizumab on food allergy threshold in children with severe food allergy","volume":"79","author":"Mortz","year":"2024","journal-title":"Allergy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"randomized, double\u2212blind, parallel\u2212group, placebo\u2212controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow\u2019s milk allergy","volume":"137","author":"Wood","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17453","DOI":"10.1038\/s41598-017-16730-6","article-title":"Oral immunotherapy combined with omalizumab for high-risk cow\u2019s milk allergy: a randomized controlled trial","volume":"7","author":"Takahashi","year":"2017","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/all.14107","article-title":"Trends in egg specific immunoglobulin levels during natural tolerance and oral immunotherapy","volume":"75","author":"Andorf","year":"2019","journal-title":"Allergy"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy.","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312382","article-title":"Omalizumab for the Treatment of Multiple Food Allergies","volume":"390","author":"Wood","year":"2024","journal-title":". New England Journal of Medicine"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8677-0","article-title":"Oral and sublingual immunotherapy for treatment of igE-mediated food allergy","volume":"55","author":"Scurlock","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jaip.2020.12.029","article-title":"Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study","volume":"9","author":"Vickery","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000361025","article-title":"Clinical studies in oral allergen-specific immunotherapy: differences among allergens","volume":"164","author":"Sato","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30420-9","article-title":"Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety","volume":"393","author":"Chu","year":"2019","journal-title":"Lancet (London England)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/all.16404","article-title":"Efficacy and safety of dupilumab in children with peanut allergy: A multicenter, open-label, phase II study","volume":"80","author":"Sindher","year":"2025","journal-title":"Allergy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.03.019","article-title":"A practical guide for implementing omalizumab therapy for food allergy","volume":"153","author":"Casale","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-014-0107-z","article-title":"Omalizumab in children","volume":"16","author":"Amelia","year":"2014","journal-title":"Paediatr Drugs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1097\/jxx.0000000000000905","article-title":"Exploring novel approaches to food allergy management","volume":"35","author":"Howard-Ruben","year":"2023","journal-title":"J Am Assoc Nurse Pract"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in igE-mediated food allergy: A systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/all.16314","article-title":"Omalizumab reduces anaphylactic reactions and allows food introduction in food-allergic in children with severe asthma: An observational study","volume":"80","author":"Arasi","year":"2025","journal-title":"Allergy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/jaa.S475517","article-title":"Does comorbid food allergy affect response to omalizumab in patients with asthma","volume":"17","author":"Fiocchi","year":"2024","journal-title":"J Asthma Allergy"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030437","article-title":"Omalizumab and oral immunotherapy in igE-mediated food allergy in children: A systematic review and a meta-analysis","volume":"18","author":"Buono","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.12.011","article-title":"Treatment of food allergy: immunotherapy, omalizumab, or both","volume":"13","author":"Brough","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12767","article-title":"Combining anti-IgE with oral immunotherapy","volume":"28","author":"Lin","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-10-7","article-title":"Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab","volume":"10","author":"B\u00e9gin","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/life15050681","article-title":"Omalizumab in food allergy in children: current evidence and future perspectives","volume":"15","author":"Indolfi","year":"2025","journal-title":"Life (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1690650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T04:13:10Z","timestamp":1761192790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1690650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2025.1690650"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1690650","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"article-number":"1690650"}}